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ABSTRACT
Objective: The objective of the present study was to develop sustained release (SR) matrix tablets of levosulpiride using natural polymers.
Methods: The tablets were prepared with different ratios of chitosan, xanthan gum, and guar gum by wet granulation technique. The solubility study 
of the levosulpiride was conducted to select a suitable dissolution media for in vitro drug release studies.
Results: Fourier transform infrared (IR) study revealed no considerable changes in IR peak of levosulpiride and hence no interaction between drug and 
the excipients. Differential scanning calorimetry thermograms showed that no drug interaction occurred during the manufacturing process. In vitro 
dissolution study was carried out for all the formulation and the results compared with marketed SR tablet. In vitro release from the formulation 
LF3 was found to be 94.53%. Hardness of LF3 was found to be 7.96±0.06 kg/cm2. Higher hardness tablets contain a compact mass of polymer with 
relatively less pore, resulting in slower release. The drug release from matrix tablets was found to decrease with increase in polymer ratio of chitosan, 
xanthan gum, and guar gum.
Conclusion: Formulation LF3 exhibited almost similar drug release profile in dissolution media as that of marketed tablets. From the results of 
dissolution data fitted to various drug release kinetic equations, it was observed that highest correlation was found for first order, Higuchi’s and 
Korsmeyer equation, which indicate that the drug release occurred through diffusion mechanism.
Keywords: Levosulpiride, Sustained release tablets, Natural polymers, In vitro drug release studies.
INTRODUCTION
In the recent years, sustained release (SR) drug delivery systems are 
gaining more interest as these systems deliver the drug continuously for 
prolonged period to maintain the steady state blood level concentration, 
therefore providing reduction in the dosing frequency and increasing 
better patient compliance. These systems are designed mainly for the 
drugs which are required to be taken frequently [1].
These SR drug delivery systems are prepared using natural or synthetic or 
semi-synthetic polymers. They offer many advantages such as enhanced 
bioavailability, site-specific drug delivery, SR of drug over longer period, 
retention of formulation in entire length of gastrointestinal tract, release 
of desired concentration of drug at targeted site, and improved patient 
compliance due to reduction in frequent dosing [2].
Since levosulpiride requires frequent dosing to maintain therapeutic 
drug concentration, it was chosen as an ideal candidate for SR dosage 
form. Matrix tablets are prepared either wet granulation/direct 
compression method. The study is conducted to design and evaluate the 
SR tablets of levosulpiride [3,4] with natural polymers such as chitosan, 
xanthan gum, and guar gum.
Chitosan, xanthan gum, and guar gum were selected for this study 
based on its non-toxic nature, easy compression, swelling properties, 
and accommodation to high level of drug loading [5].
The objective of the present study is to develop an SR tablet of 
levosulpiride which release the drug in a sustained manner over a 
period of 12 hrs, using different natural polymers and study on polymer 
concentration effect on release pattern.
MATERIALS AND METHODS
Materials
Levosulpiride was obtained as a gift sample from Sunglow 
Pharmaceuticals, Puducherry. Chitosan, xanthan gum, and guar gum 
were purchased from Sigma Aldrich. Microcrystalline cellulose, 
polyvinylpyrrolidone, and magnesium stearate were purchased from 
Chemika-Biochemika-Reagents, Mumbai, Maharashtra, India. All 
other chemicals and reagents used for these studies were of analytical 
grade.
Methods
Formulation of levosulpiride SR tablets
The levosulpiride SR tablets were prepared by wet granulation 
technique [6]. Composition of SR tablets of levosulpiride is given in 
(Table 1) Levosulpiride was passed through sieve # 40. The release-
retarding polymers, namely, chitosan, xanthan gum, and guar gum 
and additive microcrystalline cellulose and magnesium stearate as 
glidants, were passed through sieve # 60. Polyvinylpyrrolidone and 
isopropyl alcohol was used as granulating agent to get coherent 
mass. The wet granules were dried at room temperature. The dried 
granules were passed through sieve no # 14. Mixed with magnesium 
stearate and compressed into tablets on a 16 station Rotary Cadmach 
Machine.
Drug excipient compatibility studies
Infrared (IR) spectroscopy
IR spectroscopy was conducted using a Shimadzu Fourier transform 
IR 8300 spectrophotometer, and the spectrum was recorded in the 
wavelength region 4000-400/cm [7].
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Differential scanning calorimetry (DSC)
DSC (Shimadzu DSC-60, Japan)was used to examine the thermal 
behavior of pure drug and drug-additive mixtures. DSC thermograms of 




Angle of repose was determined using fixed funnel method. The 
blend was poured through a funnel that can be raised vertically until 
a maximum cone height (h) was obtained. Radius of the heap (r) was 
measured, and angle of repose was calculated using formula [7]:
θ=tan−1(h/r)
where θ is angle of repose, h is height of pile, and r is the radius of the 
base pile.
Loose bulk density (LBD)
Apparent LBD was determined by pouring blend into a graduated 
cylinder. The bulk volume (Vo) and weight of powder (M) were 
determined. The LBD was calculated using the formula [8]:
LBD=Weight of the powder (M)/volume of the packing (Vo)
Tapped bulk density (TBD)
The measuring cylinder containing known mass of blend was tapped 
for a fixed time. The minimum volume (Vt) occupied in the cylinder 
and weight of powder blend (M) as measured. The TBD was calculated 
using the formula [7]:
TBD=Weight of the powder (M)/tapped volume of the packing (Vt)
Carr’s compressibility index
The simplex way of measurement of the free flow of powder is 
compressibility, an indication of the ease with which a material can be 
induced to flow is given by compressibility index of the granules was 
determined by Carr’s compressibility index (C) which is calculated 
using the following formula [9]:
C=[(TBD−LBDTB)]×100
Hausner ratio
Hausner ratio is an indirect index of ease of powder flow. It is calculated 
by the following formula [9]:
Hausner’s ratio=Tapped bulk density (TBD)/ Loose bulk density (LBD)
where TBD is tapped bulk density and LBD is loose bulk density. Lower 
Hausner ratio (<1.25) indicates better flow properties than higher ones 
(>1.25).
Post compression parameters
All 9 batches of tablets were evaluated for various parameters such as 
weight variation, friability, hardness, drug content, disintegration, and 
dissolution, and results are reported in Table 3.
Uniformity of weight
This test is performed to maintain the uniformity of weight of each 
tablet which should be in the prescribed range, this is done by sampling 
and weighing 20 tablets at random and average weight is calculated. 
Not more than two of the individual weights deviate from the average 
weight by more than the percentage show in Table 3, and none deviate 
by more than twice the percentage. The mean and standard deviation 
were determined [7].
Thickness
The thickness and diameter of the tablets were determined using a 
micrometer screw gauge. Totally, 5 tablets from each type of formulation 
were used and average values were calculated. It is expressed in 
mm [7,9].
Table 1: Preparation of levosulpiride SR tablets LF1‑LF9
S. No Ingredients (mg) Formulation code
LF1 LF2 LF3 LF4 LF5 LF6 LF7 LF8 LF9
1 Levosulpiride 75 75 75 75 75 75 75 75 75
2 Chitosan 25 50 75 - - - - - -
3 Xanthan gum - - - 25 50 75 - - -
4 Guar gum - - - - - - 25 50 75
5 MCC 93.2 68.2 43.2 93.2 68.2 43.2 93.2 68.2 43.2
6 PVP K30 4.6 4.6 4.6 4.6 4.6 4.6 4.6 4.6 4.6
7 Isopropyl alcohol Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S
8 Magnesium stearate 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2 2.2
9 Total weight 200 200 200 200 200 200 200 200 200
SR: Sustained release, PVP: Polyvinylpyrrolidone, MCC: Microcrystalline cellulose
Table 2: Physical characteristics of levosulpiride SR matrix tablets
Formulation code Angle of 
repose (°)*
Loose bulk density (g/ml)* Tapped bulk density (g/ml)* Hausner ratio* Carr’s 
index (%)*
LF1 22.37±0.80 0.734±0.01 0.845±0.01 1.15±0.01 13.103±0.41
LF2 23.20±0.80 0.713±0.02 0.822±0.02 1.15±0.01 13.224±0.41
LF3 22.70±0.80 0.726±0.02 0.840±0.02 1.15±0.01 13.340±0.41
LF4 23.70±0.30 0.721±0.01 0.833±0.01 1.16±0.01 13.485±0.66
LF5 23.80±0.30 0.732±0.01 0.788±0.04 1.16±0.01 14.016±0.69
LF6 23.93±0.45 0.739±0.01 0.859±0.01 1.16±0.00 13.968±0.22
LF7 23.37±0.84 0.646±0.02 0.753±0.02 1.17±0.01 14.231±0.86
LF8 23.23±0.45 0.676±0.04 0.788±0.04 1.17±0.01 14.204±0.89
LF9 23.83±0.35 0.677±0.03 0.788±0.03 1.17±0.01 14.182±0.69
Standards 20-30 - - <1.25 12-16
*All the values were expressed as mean±SD, n=3, SR: Sustained release, SD: Standard deviation
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Hardness test
The hardness of the tablet was determined using Monsanto hardness 
tester [7,9].
Friability test
A number of 6 tablets from each batch were examined for friability using 
Roche Friabilator (Tropical Equipment Pvt. Ltd. Mumbai, Maharashtra, 
India)and the equipment was run for 4 minutes at 25 revolutions per 
minute. The tablets were taken out, dedusted, and reweighted and 
percentage friability was calculated [7].
Percent friability=Initial weight−Final weight×100/Initial weight
In vitro drug release studies
In vitro dissolution [10-13] profile of each formulation was 
determined by the United States Pharmacopeia, 21st revision (USP 
XXI) dissolution test apparatus (Apparatus II)method. The prepared 
levosulpiride tablets were placed inside the dissolution test apparatus 
filled with 900 ml of phosphate buffer pH 6.8as dissolution medium. 
At predetermined time intervals, the sample was withdrawn, and the 
amount of levosulpiride released was determined by measuring the 
absorbance at 292 nm using a UV-visible spectrophotometer. From 
the absorbance values, the cumulative percentage drug release was 
calculated.
Stability studies
Stability studies were performed as per the International Conference 
on Harmonization (ICH) guidelines [8,14] on formulation LF3. Selected 
formulation (LF3) was strip pack and stored at 25±2°C with 60±5% RH 
and 40±2°C with 75±5% RH for 3 months. Samples were analyzed 
after storage for 1, 2, 3, 6, 9, and 12 months. They were evaluated 




Levosulpiride SR tablets were prepared with different 
concentrations of chitosan, xanthan gum, and guar gum and were 
optimized by conducting various trials. The levosulpiride SR tablets 
were prepared by wet granulation technique. The drug release from 
the matrix tablets was found to be decrease with increase in drug 
polymer ratio.
Drug excipient compatibility studies
The IR spectra of pure levosulpiride as well as its mixture (1:1) with 
excipients showed 2966.6, 1619.3, 1589.0, 1339.2, and 916.2/cm wave 
number as major peaks. The results revealed no considerable changes 
in IR peak of levosulpiride and hence no interaction between drug and 
the excipients. DSC thermograms showed that no drug interaction 
occurred during the manufacturing process (Figs. 1-8).
Precompression parameters
The powders prepared for compression of SR tablets were evaluated 
for their flow properties; the results are shown in Table 2. The angle 
of repose was in the range of 22.37±0.80-23.93±0.45 which indicates 
excellent flow of the powder for all formulations. The LBD of the powder 
formulation was in the range of 0.646±0.02-0.739±0.01 g/ml; the TBD 
was in the range of 0.753±0.02-0.859±0.01 g/ml, which indicates that 
the powder was not bulky. The Carr’s index was found to be in the range 
of 13.10±0.41-14.23±0.86, and the Hausner ratio was found to be in 
the range of 1.15±0.01-1.17±0.01, indicating compressibility of the 
tablet blend is good. Hausner ratio was <1.25 for all batches indicating 
good flow properties. These values indicate that the prepared powders 
exhibited good flow properties.
Post compression parameters
The results of physicochemical characterizations are shown in Table 3. 
Thickness and diameter specifications may be set on an individual 
product basis. Excessive variation in the tablet thickness and diameter 
can result in problems with packaging as well as consumer acceptance. 
The thickness of matrix tablets was measured by vernier caliper and was 
ranged between 3.71±0.03 and 3.87±0.06 mm for all formulation [15]. 
The weight variation for different formulations (LF1-LF9) was found 
to be 197.99±1.57-199.20±1.41, showing satisfactory results as per the 
Indian Pharmacopoeia limit. The hardness of the matrix tablets was 
measured by Monsanto tester and was controlled between 7.26±0.06 
and 7.96±0.06 kg/cm2. This indicates good mechanical strength of 
tablet. The friability was below 1% for all the formulations, which 
is an indication of good mechanical resistance of the tablet. The 
percentage of drug content for LF1 to LF9 was found to be in between 
98.47±0.15 and 100.17±0.67% of levosulpiride; it complies with official 
specifications [1,16].
Fig. 1: Fourier transform infrared spectrum of levosulpiride
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Fig. 2: Fourier transform infrared spectrum of levosulpiride with chitosan
Fig. 3: Fourier transform infrared spectrum of levosulpiride with xanthan gum
Table 3: Physicochemical characteristics of levosulpiride SR matrix tablets
Formulation code Dimensions (mm) Hardness (kg/cm2) Friability (%) Weight variation (mg) Drug content (% w/w)
Diameter Thickness
LF1 7.70±0.05 3.87±0.06 7.37±0.02 0.278±0.00 197.99±1.57 98.47±0.15
LF2 7.80±0.04 3.83±0.04 7.38±0.04 0.288±0.00 198.53±1.03 98.52±0.36
LF3 7.78±0.06 3.87±0.04 7.96±0.06 0.288±0.00 199.18±1.61 99.45±0.30
LF4 7.88±0.03 3.78±0.03 7.75±0.03 0.288±0.00 198.64±1.30 99.64±0.53
LF5 7.97±0.03 3.72±0.04 7.26±0.06 0.288±0.00 198.87±1.14 100.13±0.24
LF6 7.81±0.04 3.78±0.03 7.87±0.04 0.283±0.00 198.59±1.12 99.48±0.35
LF7 7.58±0.05 3.71±0.03 7.91±0.03 0.284±0.00 199.12±1.61 100.10±0.21
LF8 7.42±0.05 3.71±0.04 7.95±0.03 0.286±0.00 199.20±1.41 100.17±0.67
LF9 7.57±0.05 3.72±0.04 7.48±0.05 0.273±0.00 198.74±1.02 98.47±0.39
M1 7.72±0.03 3.76±0.04 7.94±0.04 0.280±0.00 198.94±1.61 100.08±0.58
Standards - - 4-8 <1 ±7.5 98-102
All the values were expressed as mean±SD, n=3, SR: Sustained release, SD: Standard deviation
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Fig. 4: Fourier transform infrared spectrum of levosulpiride with guar gum
Fig. 5: Differential scanning calorimetry thermal analysis of levosulpiride
In vitro drug release studies
In vitro dissolution study was carried out for all the formulations as 
well as the marketed formulation (M1) using USPXXI dissolution test 
apparatus [6]. The drug release from the matrix tablets was found to be 
decrease with increase in drug polymer ratio. The drug released from 
formulation LF1 to LF3 containing chitosan at 3 concentration levels 
of 25%, 50%, and 75% were found to be 95.53±0.89, 95.14±1.59, and 
94.98±1.39% for levosulpiride at the end of 10th, 11th, and 12th hrs, 
respectively. The drug released from formulation LF4 to LF6 containing 
Xanthan gum at 3 concentration levels of 25%, 50%, and 75% were 
Table 4: Stability studies of levosulpiride SR matrix tablets LF3
Stability chamber Time
(months)
Appearance Hardness (kg/cm²) Friability (%) Drug content (%) % Drug release
25±2°C with 60±5% RH Initial White 7.96±0.06 0.288±0.00 99.45±0.30 94.98±1.39
1 No change 7.93±0.08 0.286±0.00 99.41±0.35 94.40±0.16
2 No change 7.90±0.07 0.283±0.00 99.38±0.27 94.24±0.07
3 No change 7.86±0.08 0.281±0.00 99.35±0.36 94.15±0.05
6 No change 7.83±0.05 0.279±0.00 99.31±0.29 94.08±0.09
9 No change 7.83±0.06 0.274±0.00 99.28±0.21 94.02±0.11
12 No change 7.82±0.07 0.271±0.00 99.25±0.65 93.94±0.09
All the values were expressed as mean±SD, n=3, SR: Sustained release, SD: Standard deviation
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found to be 96.41±1.54, 95.08±0.29, and 94.83±1.42% for levosulpiride 
at the end of 9th, 10th, and 11th hrs, respectively.
The drug released from formulation LF7 to LF9 containing guar 
gum at 3 concentration levels of 25%, 50%, and 75% were found to 
be 95.07±1.48%, 94.73±1.41, and 94.40±2.78 for levosulpiride at 
the end of 8th, 9th, and 10th hrs, respectively. In vitro release from the 
formulation LF3 was found to be 94.53%. Hardness of LF3 was found 
to be 7.96±0.06 kg/cm2. Higher hardness tablets contain a compact 
mass of polymer with relatively less pore, resulting in slower release. 
Fig. 6: Differential scanning calorimetry thermal analysis of levosulpiride with chitosan
Fig. 7: Differential scanning calorimetry thermal analysis of levosulpiride with xanthan gum
Table 5: Stability studies of levosulpiride SR matrix tablets LF3
Stability chamber Time
(months)
Appearance Hardness (kg/cm²) Friability (%) Drug content (%) % Drug release
40±2°C with 75±5% RH Initial White 7.96±0.06 0.288±0.00 99.45±0.30 94.98±1.39
1 No change 7.94±0.10 0.285±0.42 99.43±0.67 94.47±0.46
2 No change 7.91±0.28 0.280±0.75 99.40±0.81 94.39±0.92
3 No change 7.87±0.53 0.278±0.32 99.37±0.26 94.30±0.23
6 No change 7.86±0.65 0.275±0.75 99.35±0.78 94.28±0.54
9 No change 7.85±0.24 0.274±0.65 99.33±0.36 94.27±0.85
12 No change 7.82±0.35 0.270±0.54 99.01±0.76 94.05±0.42
All the values were expressed as mean±SD, n=3, SR: Sustained release, SD: Standard deviation
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Fig. 8: Differential scanning calorimetry thermal analysis of levosulpiride with guar gum
Fig. 9: In vitro drug release of levosulpiride sustained release matrix tablets
All other tested parameters of LF3 formulation were in the acceptable 
limits. Hence, the formulation LF3 was found to be better than other 
batch of formulations.
When the data were plotted according to zero-order equation, the 
formulations showed a fair linearity, with regression value between 
0.983 and 0.994. The correlation values of first order and Higuchi’s 
equation of all the formulations were found to be 0.932-0.969 and 
0.971-0.986. To confirm the super case II transport mechanism, the 
data were fit into Korsmeyer equation 0.987 to 0.998 [16] (Fig. 9).
Stability studies
Stability studies were performed as per the ICH guidelines on 
formulation LF3 [14]. The levosulpiride content was found to be 
within the acceptable limit. The cumulative drug release profile 
was found to be uniform. All other tested parameters (appearance, 
hardness, and friability) within the acceptable limit. The prepared 
formulation was found to be stable. Data of stability studies are shown 
in Tables 4 and 5
CONCLUSION
In this study, an effort was made to study SR levosulpiride tablets which 
can provide sustained drug release for up to 12 hrs. Levosulpiride SR 
tablets were formulated and evaluated. Levosulpiride SR tablets were 
prepared with different concentrations of chitosan, xanthan gum, 
and guar gum and were optimized by conducting various trials. The 
optimization procedure aided in the preparation of levosulpiride SR 
tablets with sustained drug release up to 12 hrs. The in vitro dissolution 
studies revealed that the formulated levosulpiride SR tablets released 
the desired concentration of the drug. Stability study as per the ICH 
guidelines was carried out and found to be stable. Hence, it may be 
concluded that the newly formulated levosulpiride SR tablets can be 
ideal and suitable for the treatment of psychiatric patients.
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